Perrigo (PRGO) Cash & Equivalents (2012 - 2026)
Perrigo's (PRGO) quarterly Cash & Equivalents came in at $357.2 million in Q1 2026, down 12.86% year-on-year from $409.9 million in Q1 2025, and down 32.81% on a QoQ basis from $531.6 million in Q4 2025.
Perrigo (PRGO) Cash & Equivalents (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has 15 years of Cash & Equivalents data on file, last reported at $357.2 million in Q1 2026.
- On a quarterly basis, Cash & Equivalents fell 12.86% year-over-year to $357.2 million in Q1 2026; TTM through Mar 2026 was $357.2 million, a 12.86% decrease from a year earlier, with the FY2025 full-year figure at $531.6 million, down 4.87% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $357.2 million, down from $531.6 million in the prior quarter.
- Over the last five years, Cash & Equivalents for PRGO reached as high as $2.0 billion in Q2 2022 and fell as low as $357.2 million in Q1 2026.
- Historically, Cash & Equivalents has averaged $669.8 million across 5 years, with a median of $553.0 million in 2023.
- On a YoY basis, Cash & Equivalents climbed as much as 317.39% in 2022 and fell as far as 77.45% in 2022.
- Year by year, Cash & Equivalents stood at $600.7 million in 2022, then increased by 25.07% to $751.3 million in 2023, then declined by 25.62% to $558.8 million in 2024, then dropped by 4.87% to $531.6 million in 2025, then plunged by 32.81% to $357.2 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $357.2 million in Q1 2026, $531.6 million in Q4 2025, and $432.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 357.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 357.20 Mn |
| Dec 31, 2025 | 531.60 Mn |
| Sep 27, 2025 | 432.10 Mn |
| Jun 28, 2025 | 454.20 Mn |
| Mar 29, 2025 | 409.90 Mn |
| Dec 31, 2024 | 558.80 Mn |
| Sep 28, 2024 | 1.46 Bn |
| Jun 29, 2024 | 542.80 Mn |
| Mar 30, 2024 | 658.50 Mn |
| Dec 31, 2023 | 751.30 Mn |
| Sep 30, 2023 | 598.30 Mn |
| Jul 1, 2023 | 555.20 Mn |
| Apr 1, 2023 | 553.00 Mn |
| Dec 31, 2022 | 600.70 Mn |
| Oct 1, 2022 | 468.70 Mn |
| Jul 2, 2022 | 485.30 Mn |
| Apr 2, 2022 | 1.97 Bn |
| Dec 31, 2021 | 1.86 Bn |
| Oct 2, 2021 | 2.08 Bn |
| Jul 3, 2021 | 317.50 Mn |